- Home
- WLAC vs ESPR Comparison
WLAC vs ESPR Comparison
Compare WLAC & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLAC
- ESPR
- Stock Information
- Founded
- WLAC 2024
- ESPR 2008
- Country
- WLAC United States
- ESPR United States
- Employees
- WLAC N/A
- ESPR N/A
- Industry
- WLAC
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- WLAC
- ESPR Health Care
- Exchange
- WLAC Nasdaq
- ESPR Nasdaq
- Market Cap
- WLAC 172.6M
- ESPR 202.2M
- IPO Year
- WLAC 2024
- ESPR 2013
- Fundamental
- Price
- WLAC $10.22
- ESPR $1.20
- Analyst Decision
- WLAC
- ESPR Buy
- Analyst Count
- WLAC 0
- ESPR 6
- Target Price
- WLAC N/A
- ESPR $6.50
- AVG Volume (30 Days)
- WLAC 65.0K
- ESPR 3.1M
- Earning Date
- WLAC 01-01-0001
- ESPR 08-11-2025
- Dividend Yield
- WLAC N/A
- ESPR N/A
- EPS Growth
- WLAC N/A
- ESPR N/A
- EPS
- WLAC N/A
- ESPR N/A
- Revenue
- WLAC N/A
- ESPR $259,574,000.00
- Revenue This Year
- WLAC N/A
- ESPR $4.07
- Revenue Next Year
- WLAC N/A
- ESPR N/A
- P/E Ratio
- WLAC $755.36
- ESPR N/A
- Revenue Growth
- WLAC N/A
- ESPR 12.99
- 52 Week Low
- WLAC $9.80
- ESPR $0.69
- 52 Week High
- WLAC $10.60
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- WLAC N/A
- ESPR 63.86
- Support Level
- WLAC N/A
- ESPR $1.10
- Resistance Level
- WLAC N/A
- ESPR $1.26
- Average True Range (ATR)
- WLAC 0.00
- ESPR 0.08
- MACD
- WLAC 0.00
- ESPR 0.02
- Stochastic Oscillator
- WLAC 0.00
- ESPR 93.55
About WLAC Willow Lane Acquisition Corp. Class A Ordinary Shares
Willow Lane Acquisition Corp is a blank check company.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.